These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: 18F-fluorodeoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis.
    Author: Nakajo M, Jinnouchi S, Tanabe H, Tateno R, Nakajo M.
    Journal: J Comput Assist Tomogr; 2007; 31(4):539-43. PubMed ID: 17882028.
    Abstract:
    OBJECTIVE: To evaluate the 18F-fluorodeoxyglucose (FDG) uptake features of idiopathic retroperitoneal fibrosis (IRF). METHODS: 18F-Fluorodeoxyglucose positron emission tomographic (PET) or PET/computed tomographic findings were retrospectively reviewed in 6 patients with IRF. FDG PET or PET/computed tomography was performed 1 and 2 hours after FDG injection. The FDG level was scored using a 4-point scale, and the intensity of FDG uptake was quantified using the maximum standardized uptake value (SUVmax). RESULTS: In the 1-hours images, intense FDG uptake by IRF was observed in 5 patients before steroid treatment, but no abnormal uptake was noted in 1 patient receiving steroid treatment. The SUVmax in IRF increased from a mean +/- SD of 6.0 +/- 1.2 (range, 4.9-7.6) to 7.6 +/- 1.1 (range, 5.9-8.2) for all 4 patients who underwent 1 and 2 hours dual-time point imaging. Abnormal uptake was also noted in the mediastinum and the pancreas in 1 and 2 patients, and the diagnoses of mediastinal fibrosis and autoimmune pancreatitis were made, respectively. The SUVmax was stable or increased in the 3 lesions of mediastinal fibrosis and autoimmune pancreatitis. CONCLUSION: FDG PET may be a reliable means of evaluating disease activity and the extent of IRF, but dual-time point imaging may not be useful to differentiate malignancy from IRF.
    [Abstract] [Full Text] [Related] [New Search]